Tumor Registry Pancreatic Cancer (AMETHYST)

iOMEDICO

Status: Completed

Conditions: Pancreas Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT02089269

Tumorregister Pankreaskarzinom (Other Identifier)

iOM-01281

Details and patient eligibility

About

The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.

Enrollment: 2,325 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• resectable or locally advanced/metastatic pancreatic cancer
• 18 years and older
• Antineoplastic treatment
• Date of consent no later than 2 weeks after start of first-line treatment

Exclusion criteria

• No pancreatic cancer
• Below 18 years and older
• No antineoplastic treatment
• Date of consent later than 2 weeks after start of first-line treatment

Trial design

2,325 participants in 2 patient groups

Cohort 1

Description:

2,200 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention

Cohort 2

Description:

125 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention